27.09.2012
- Hovione today announced the expansion of its solutions to solve issues of poor bioavailability, patient acceptability and the enabling of optimal delivery for non-oral routes of...
31.08.2012
- Hovione announced the appointment of Dr. Mike Ironside as General Manager, TTC in New Jersey. Dr. Ironside was previously with GSK in the UK and with AMRI and most recently with...
28.08.2012
- Hovione announced the appointment of Dr. Conrad Winters as Director, Drug Product Development. Dr. Winters was previously with Merck and most recently with Xenon Pharmaceuticals...
25.06.2012
- Hovione announced that the consolidated sales for the fiscal year ended March 2012 amounted to $180 million, the sixth consecutive year of sales growth, representing a growth of 24...
15.03.2012
- Hovione announced the appointment of Dr. Colin Minchom as Vice President of its Particle Design Business Unit. Dr. Minchom was most recently with Patheon where he held the position...
15.03.2012
- Hovione said it has appointed Dr. Colin Minchom as vice president of its Particle Design business unit. Dr. Minchom was most recently with Patheon where he held the position of...
14.04.2011
- Tony Scott credits Hovione CEO Guy Villax with coining the phrase, "saints and sinners" when referring to the notoriously uneven playing field in the world of API and excipient...
04.11.2010
- The U.S. Patent and Trademark's Board of Patent Appeals and Interferences has reconfirmed Hovione's patent claims to a method of making flumethasone and its 17-carboxyl androsten...
